By annette
I3LUNG leads the way towards personalized oncology through artificial intelligence For the third consecutive year, Michael Willis, Research Director at IHE alongside the other partners of the I3LUNG consortium, an EU-funded project under the Horizon 2020 programme, have gathered for their annual meeting to share progress and reinforce their position as pioneers in the application …
By annette
The results for Portugal from the Cancer Comparator Report 2025 were presented at the conference Oncology 2030 – Innovation Challenges in the Fight Against Cancer organized by APIFARMA – Portuguese Pharmaceutical Industry Association. Some findings: Portugal has the 8th highest cancer incidence rate and the 9th highest cancer mortality rate in Europe. Spending on cancer …
By annette
The launch of the Cancer Comparator Report 2025 has created a lot of interest in Latvia. The uptake of new cancer medicines in Latvia is the lowest in the EU. Despite improvements in cancer survival over the last two decades, patients in Latvia still face challenges in accessing care on the same level as European …
By annette
At the 2025 ASCO Annual Meeting, IHE presents a poster on “The development of the cost of cancer in 31 European countries”, authored together with Dr. Christer Svedman and Prof. Nils Wilking. Poster synopsis: Cancer poses a significant economic burden on societies. This cost-of-illness study estimated the direct and indirect costs of cancer across 31 …
By annette
The Swedish Institute for Health Economics welcomes a new colleague, Urška Košir, as the new Project Manager in cancer policy.
By annette
A new registry-based study from IHE has evaluated if clinical outcomes and health-related quality of life (HRQoL) in Parkinson’s disease differ depending on whether patients meet the so-called 5-2-1 criteria. The criteria, which are based on motor symptoms, aim to identify patients with insufficient symptom control from oral medication. The results indicate a higher disease …
By annette
IHE participates at the conference with a poster presentation on the importance of using the right prices in the U.S., tailoring your analysis to the question at hand. Poster presentation Tailoring Generalized Cost-Effectiveness Analysis (GCEA) to the U.S. Setting: The Importance of Using the Right Prices Name of authors: Willis Michael, Nilsson Andreas and Neslusan Chery Name …
By annette
This IHE report questions the accuracy and reliability of using standardized drug administration tariffs from publicly available price lists, such as the Southern Healthcare Region’s Price List (SSPL) in Sweden, in health economic evaluations. These tariffs include unrelated costs (such as the drugs themselves, accounting for up to 76% of the total cost), lack granularity, …
By annette
At the 14th Baltic Hematology Conference, Thomas Hofmarcher gave a presentation about findings from the IHE Report “Comparator Report on Cancer in Europe 2025“. The presentation focused on the Baltic countries and hematology. Spending on cancer care, uptake of new medicines, and survival outcomes of cancer patients are all below the EU-average in the three …
By annette
Cancer Patients Europe (CPE) organized a high-level event at the European Parliament on 23rd April hosted by MEP Tomislav Sokol to mark the launch of “the Call to Action: 5 Ways to Reduce Cancer Care Inequalities in Europe”. IHE contributed to the evidence base of this Call to Action through the IHE Report on “Tackling …